Related Experiment Video
Updated: May 6, 2026

07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.5K
Active surveillance in men with localized prostate cancer: a systematic review
Issa J Dahabreh1, Mei Chung, Ethan M Balk
1Tufts Evidence-based Practice Center, Institute for Clinical Research and Health Policy Studies, Boston, Massachusetts, USA.
Annals of Internal Medicine
|February 22, 2012
Summary
Active surveillance (AS) and watchful waiting (WW) are management strategies for low-risk prostate cancer. Evidence is insufficient to determine if AS is appropriate, and a standard definition is needed.
Area of Science:
- Oncology
- Urology
- Clinical Management
Background:
- Active surveillance (AS) and watchful waiting (WW) are proposed management strategies for low-risk, localized prostate cancer.
- These observational approaches aim to defer or avoid immediate treatment with curative intent.
Purpose of the Study:
- To systematically review observational management strategies (AS or WW) for prostate cancer.
- To identify factors influencing the utilization of AS and WW.
- To compare the effectiveness of observational management versus immediate treatment with curative intent.
Main Methods:
- Systematic review of MEDLINE and Cochrane databases (inception to August 2011).
- Screening of abstracts and full-text publications for eligible studies.
- Data extraction by one reviewer, verification by another; study quality and strength of evidence rated by two independent reviewers.
Main Results:
- Sixteen cohorts defined AS criteria (tumor stage, Gleason score, PSA, biopsy cores).
- Monitoring commonly involved PSA testing, digital rectal exams, and rebiopsies.
- Watchful waiting was generally less effective than curative treatment, but applicability to current patients may be limited.
- No studies directly compared AS with immediate curative treatment.
Conclusions:
- Active surveillance and watchful waiting were often indistinguishable in reviewed studies.
- Published randomized trials focused only on WW and excluded PSA-screened patients.
- Insufficient evidence exists to confirm AS as an appropriate option for localized prostate cancer; a standardized definition is required.

